Treatment Optimization and Management of AEs with EV + P for Untreated Locally Advanced/Metastatic Urothelial Cancer

Show notes

In this podcast "Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast", authors discuss the management of adverse events (AEs) with enfortumab vedotin + pembrolizumab based on their personal experiences with clinical trials and in their practices and provide perspectives for healthcare professionals on practical management of common AEs and effective dose management strategies. This may help improve the patient experience and allow patients to stay on therapy for longer, leading to optimized treatment outcomes.

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00369-9.
All conflicts of interest can be found online. This podcast is intended for medical professionals.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.